Progenics Pharmaceuticals, Inc. (PGNX)
$4.07
0.08 (+2.01%)
| CAPS Rating |
|
|---|---|
| Open | $3.99 |
| Previous Close | $3.99 |
| Daily Range | $3.93 - $4.09 |
| 52-Week Range | $3.53 - $10.81 |
| Market Cap | $128.87M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 307,663 |
| Average Daily Volume | 186,000 |
PGNX
VS S&P 500 (SPY)
How do you think PGNX will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
PGNX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
PGNX News and Commentary
- Pain drug morphine may accelerate cancer growth – Reuters
- 4-Star Stocks on the Upswing – The Motley Fool
- This Partnership Will Go No Further – The Motley Fool
- Progenics regains rights to Relistor from Wyeth – Reuters
- Nektar Tastes Sweet – The Motley Fool
- Get Ready for the Bounce – The Motley Fool
- One Outrageously Cheap Stock – The Motley Fool
- 5 Cold Stocks Heating Up – The Motley Fool
- Fearful Stocks for Greedy Investors – The Motley Fool
- Efficient market? Not in Biotech. – Blog at The Motley Fool
- Will Patients Reject This Injection? – The Motley Fool
- One Outrageously Cheap Stock – The Motley Fool
- Generic Heartburn at Wyeth – The Motley Fool
- Seattle Genetics Has What Others Want – The Motley Fool
- 3 Stocks Revving Their Engines – The Motley Fool
- The Stocks the Funds Are Buying – The Motley Fool
- Wall Street's Buy List – The Motley Fool
- Closing PGNX (Progenix) outperform – Blog at The Motley Fool
- Progenics' Mixed Trial Data – The Motley Fool
- The Fortune Cookie Says ... – The Motley Fool
RSS Headlines
Fool UK
